Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials
An update from Mineralys Therapeutics, Inc. ( (MLYS) ) is now available. Mineralys Therapeutics announced that the U.S. FDA ...
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
Estimated 54 million people suffer from obstructive sleep apnea in the U.S. including 30-50% of adults with hypertension, both conditions ...
Strategic Advancements and FDA Clearance Propel Mineralys Therapeutics to a Buy Rating
Mineralys Therapeutics, Inc. (MLYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Yahoo Finance6d
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension
RADNOR, Pa., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension ...
Investing6d
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial
RADNOR, Pa. - Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company with a market capitalization of $646 million, announced today that the U.S. Food and Drug ...
Pharmabiz3d
Mineralys Therapeutics gets US FDA nod to begin phase 2 trial of lorundrostat for OSA in patients with hypertension
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated ...
Investing5d
Mineralys Therapeutics gets FDA nod for sleep apnea drug trial
RADNOR, Pa. - Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company with a market capitalization of $646 million, announced today that the U.S. Food and Drug ...